Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Accumulated Expenses: 2024

Historic Other Accumulated Expenses for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2024 value amounting to $570,000.

  • ARS Pharmaceuticals' Other Accumulated Expenses was N/A to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year change of. This contributed to the annual value of $570,000 for FY2024, which is N/A change from last year.
  • As of FY2024, ARS Pharmaceuticals' Other Accumulated Expenses stood at $570,000.
  • ARS Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $570,000 during FY2024, with a 5-year trough of $570,000 in FY2024.
  • Its 1-year average for Other Accumulated Expenses is $570,000, with a median of $570,000 in 2024.